Pharmacokinetics of marbofloxacin after a single oral dose to loggerhead sea turtles (Caretta caretta)

被引：18

作者：

Marin, P. ^{[1
]}

Lai, O. R. ^{[2
]}

Laricchiuta, P. ^{[3
]}

Marzano, G. ^{[4
]}

Di Bello, A. ^{[5
]}

Carceles, C. M. ^{[1
]}

Crescenzo, G. ^{[2
]}

机构：

[1] Univ Murcia, Fac Med Vet, Dept Pharmacol, E-30071 Murcia, Spain

[2] Univ Bari, Fac Vet Med, Dept Vet Publ Hlth, I-70010 Bari, Italy

[3] Einaudi Vet Ctr, Bari, Italy

[4] Salento Marine Turtles Rescue Ctr Bosco & Paludi, Lecce, Italy

[5] Univ Bari, Fac Vet Med, Div Vet Surg, Dept Emergency & Organ Transplantat, I-70010 Bari, Italy

来源：

RESEARCH IN VETERINARY SCIENCE | 2009年 / 87卷 / 02期

关键词：

Marbofloxacin; Pharmacokinetics; Loggerhead sea turtle; Caretta caretta; PERFORMANCE LIQUID-CHROMATOGRAPHY; FLUOROQUINOLONES; PHARMACODYNAMICS; FLUORESCENCE; ENROFLOXACIN; DANOFLOXACIN; FLUIDS;

D O I：

10.1016/j.rvsc.2009.03.012

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

The single-dose disposition kinetics of marbofloxacin (MBX) were determined in clinically healthy loggerhead sea turtles (n = 5) after oral (PO) administration of 2 mg kg(-1) bodyweight. Marbofloxacin plasma concentrations were determined by DAD-H PLC (LOD/LOQ 0.015/0.05 mu g ml(-1)). Data were subjected to non-compartmental analysis. Following PO administration, marbofloxacin achieved maximum plasma concentrations of 11.66 +/- 2.53 mg L(-1) at 15.00 +/- 3.00 h. The absence of general adverse reactions in the turtles of the study, and the favourable pharmacokinetic properties (long half-life and high maximum plasma concentration) of MBX administered PO at the single-dose of 2 mg kg(-1) suggest the possibility of its safe and effective clinical use in loggerhead sea turtles. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：284 / 286

页数：3

共 19 条

[1] Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration
Aliabadi, FS
Lees, P
[J]. AMERICAN JOURNAL OF VETERINARY RESEARCH, 2001, 62 (12) : 1979 - 1989
[2] Fluoroquinolones in animal health
Brown, SA
[J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1996, 19 (01) : 1 - 14
[3] Pharmacokinetics of marbofloxacin in blue and gold macaws (Ara ararauna)
Carpenter, James W.
Hunter, Robert P.
Olsen, John H.
Henry, Heather
Isaza, Ramiro
Koch, David E.
[J]. AMERICAN JOURNAL OF VETERINARY RESEARCH, 2006, 67 (06) : 947 - 950
[4] Preliminary single-dose pharmacokinetics of marbofloxacin in ball python']pythons (Python']Python regius)
Coke, RL
Isaza, R
Koch, DE
Pellerin, MA
Hunter, RP
[J]. JOURNAL OF ZOO AND WILDLIFE MEDICINE, 2006, 37 (01) : 6 - 10
[5] *CVMP, 1998, EMEACVMPVICH59198FIN
[6] Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones
Hannan, PCT
Windsor, GD
deJong, A
Schmeer, N
Stegemann, M
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 2037 - 2040
[7] Plasma concentrations of enrofloxacin after single-dose oral administration in loggerhead sea turtles (Caretta caretta)
Jacobson, E
Gronwall, R
Maxwell, L
Merrit, K
Harman, G
[J]. JOURNAL OF ZOO AND WILDLIFE MEDICINE, 2005, 36 (04) : 628 - 634
[8] Naive averaged, nave pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals
KuKanich, Butch
Huff, David
Riviere, Jim E.
Papich, Mark G.
[J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2007, 230 (03): : 390 - 395
[9] Pharmacodynamics of fluoroquinolones
Lode, H
Borner, K
Koeppe, P
[J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) : 33 - 39
[10] MADER DR, 2006, REPTILE MED SURG, P631

← 1 2 →